Rituximab use for refractory anti-HMGCR immune-mediated necrotizing myopathy: A case report

Sonia Gupta; Amandeep Rakhra; Vinay Thallapally; Joseph Nahas

doi:10.5582/IRDR.2020.03144

Rituximab use for refractory anti-HMGCR immune-mediated necrotizing myopathy: A case report

Sonia Gupta, Amandeep Rakhra, Vinay Thallapally, Joseph Nahas

Department of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Immunosuppression is the cornerstone therapy for anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) myopathy. Typical immunosuppressants such as corticosteroids, methotrexate, and azathioprine have been used in conjunction with removal of the offending agent, yet the use of rituximab is more limited in this type of myopathy. Reported here is a case of a patient who responded well to rituximab (RTX) after the standard immunosuppressants had failed.

Original language	English (US)
Pages (from-to)	122-125
Number of pages	4
Journal	Intractable and Rare Diseases Research
Volume	10
Issue number	2
DOIs	https://doi.org/10.5582/IRDR.2020.03144
State	Published - May 2021

All Science Journal Classification (ASJC) codes

Medicine(all)

Access to Document

10.5582/IRDR.2020.03144

Cite this

@article{dc55f1699fee425bbd549a3efc86baa5,

title = "Rituximab use for refractory anti-HMGCR immune-mediated necrotizing myopathy: A case report",

abstract = "Immunosuppression is the cornerstone therapy for anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) myopathy. Typical immunosuppressants such as corticosteroids, methotrexate, and azathioprine have been used in conjunction with removal of the offending agent, yet the use of rituximab is more limited in this type of myopathy. Reported here is a case of a patient who responded well to rituximab (RTX) after the standard immunosuppressants had failed.",

author = "Sonia Gupta and Amandeep Rakhra and Vinay Thallapally and Joseph Nahas",

year = "2021",

month = may,

doi = "10.5582/IRDR.2020.03144",

language = "English (US)",

volume = "10",

pages = "122--125",

journal = "Intractable and Rare Diseases Research",

issn = "2186-3644",

publisher = "International Advancement Center for Medicine & Health Research Co., Ltd. (IACMHR Co., Ltd.)",

number = "2",

}

TY - JOUR

T1 - Rituximab use for refractory anti-HMGCR immune-mediated necrotizing myopathy

T2 - A case report

AU - Gupta, Sonia

AU - Rakhra, Amandeep

AU - Thallapally, Vinay

AU - Nahas, Joseph

PY - 2021/5

Y1 - 2021/5

N2 - Immunosuppression is the cornerstone therapy for anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) myopathy. Typical immunosuppressants such as corticosteroids, methotrexate, and azathioprine have been used in conjunction with removal of the offending agent, yet the use of rituximab is more limited in this type of myopathy. Reported here is a case of a patient who responded well to rituximab (RTX) after the standard immunosuppressants had failed.

AB - Immunosuppression is the cornerstone therapy for anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) myopathy. Typical immunosuppressants such as corticosteroids, methotrexate, and azathioprine have been used in conjunction with removal of the offending agent, yet the use of rituximab is more limited in this type of myopathy. Reported here is a case of a patient who responded well to rituximab (RTX) after the standard immunosuppressants had failed.

UR - http://www.scopus.com/inward/record.url?scp=85108651504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85108651504&partnerID=8YFLogxK

U2 - 10.5582/IRDR.2020.03144

DO - 10.5582/IRDR.2020.03144

M3 - Article

AN - SCOPUS:85108651504

SN - 2186-3644

VL - 10

SP - 122

EP - 125

JO - Intractable and Rare Diseases Research

JF - Intractable and Rare Diseases Research

IS - 2

ER -

Rituximab use for refractory anti-HMGCR immune-mediated necrotizing myopathy: A case report

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this